The initial therapeutic effects of atomoxetine usually take 2–4 weeks to become apparent.<ref name = MSR /> A further 2–4 weeks may be required for the full therapeutic effects to be seen.<ref name="Maudsley">{{cite book | isbn = 978-0-470-97948-8 | title = The Maudsley prescribing guidelines in psychiatry | last1 = Taylor | first1 = D |author2=Paton, C |author3=Shitij, K | year = 2012 | publisher = Wiley-Blackwell | location = West Sussex  | pages =  }}</ref> Its efficacy may be less than that of stimulant medications.<ref>{{cite book|title=Adult ADHD Diagnostic Assessment and Treatment|isbn=978-1-4471-4137-2|doi=10.1007/978-1-4471-4138-9|author=Kooij, JJS|year=2013|url=https://link.springer.com/content/pdf/10.1007%2F978-1-4471-4138-9|format=PDF|publisher=Springer London}}</ref>

 
Unlike [[Alpha-adrenergic agonist|α<sub>2</sub> adrenoceptor agonists]] such as [[guanfacine]] and [[clonidine]], atomoxetine's use can be abruptly stopped without significant discontinuation effects being seen.<ref name = TGA />

 
== Adverse effects ==

 
'''<big>Incidence of adverse effects:</big>'''<ref name = TGA /><ref name = DM /><ref name = EMC>{{cite web|title=Strattera 10mg, 18mg, 25mg, 40mg, 60mg, 80mg or 100mg hard capsules|work=electronic Medicines Compendium|date=28 May 2013|accessdate=10 November 2013|url=http://www.medicines.org.uk/emc/medicine/14482/SPC/Strattera+10mg%2c+18mg%2c+25mg%2c+40mg%2c+60mg%2c+80mg+or+100mg+hard+capsules}}</ref><ref>{{cite web|title=Strattera Product Insert|accessdate=8 December 2013|url=http://medlibrary.org/lib/rx/meds/strattera-5/page/4/}}</ref>

 
'''Very common (>10% incidence) adverse effects include:'''

 
'''Common (1-10% incidence) adverse effects include:'''

 
'''Uncommon (0.1-1% incidence) adverse effects include:'''

 
'''Rare (0.01-0.1% incidence) adverse effects including:'''

 
The [[Food and Drug Administration|FDA]] of the [[United States of America|US]] has issued a [[black box warning]] for suicidal behaviour/ideation.<ref name = DM /> Similar warnings have been issued in Australia.<ref name = TGA /><ref>{{cite news|title=Atomoxetine and suicidality in children and adolescents |newspaper=Australian Prescriber |volume=36 |issue=5 |page=166 |date=October 2013 |accessdate=10 November 2013 |url=http://www.australianprescriber.com/magazine/36/5/166/9 |deadurl=yes |archiveurl=https://web.archive.org/web/20131110153948/http://www.australianprescriber.com/magazine/36/5/166/9 |archivedate=10 November 2013 |df=dmy }}</ref> Unlike stimulant medications, atomoxetine does not have abuse liability or the potential to cause withdrawal effects on abrupt discontinuation.<ref name = TGA />

 
Atomoxetine is a [[substrate (biochemistry)|substrate]] for [[CYP2D6]]. Concurrent treatment with a CYP2D6 inhibitor such as [[bupropion]], [[fluoxetine]], or [[paroxetine]] has been shown to increase plasma atomoxetine by 100% or more, as well as increase ''N''-desmethylatomoxetine levels and decrease plasma 4-hydroxyatomoxetine levels by a similar degree.<ref name = PMID27518170>{{cite journal|last1=Todor|first1=I|last2=Popa|first2=A|last3=Neag|first3=M|last4=Muntean|first4=D|last5=Bocsan|first5=C|last6=Buzoianu|first6=A|last7=Vlase|first7=L|last8=Gheldiu|first8=AM|last9=Briciu|first9=C|title=Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.|journal=Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques|date=NaN|volume=19|issue=2|pages=198–207|pmid=27518170}}</ref><ref name = PMID21765848>{{cite journal|last1=Kasi|first1=PM|last2=Mounzer|first2=R|last3=Gleeson|first3=GH|title=Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system.|journal=Case reports in medicine|date=2011|volume=2011|pages=952584|doi=10.1155/2011/952584|pmid=21765848}}</ref><ref name = PMID12412820>{{cite journal|last1=Belle|first1=DJ|last2=Ernest|first2=CS|last3=Sauer|first3=JM|last4=Smith|first4=BP|last5=Thomasson|first5=HR|last6=Witcher|first6=JW|title=Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.|journal=Journal of clinical pharmacology|date=November 2002|volume=42|issue=11|pages=1219–27|pmid=12412820}}</ref>

 
* Highly plasma protein-bound drugs: atomoxetine has the potential to displace these drugs from plasma proteins which may potentiate their adverse or toxic effects. ''In vitro'', atomoxetine does not affect the plasma protein binding of [[aspirin]], [[desipramine]], [[diazepam]], [[paroxetine]], [[phenytoin]], or [[warfarin]]<ref name = PMID15910008/><ref name = part2>{{cite web|title=21-411 Strattera Clinical Pharmacology Biopharmaceutics Review Part 2|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P2.pdf}}</ref>

 
Atomoxetine inhibits the presynaptic [[norepinephrine transporter]] (NET), preventing the reuptake of norepinephrine throughout the brain along with inhibiting the reuptake of dopamine in specific brain regions such as the prefrontal cortex, where [[dopamine transporter]] (DAT) expression is minimal.<ref name = PMID15910008/> In rats, atomoxetine increased [[prefrontal cortex]] [[catecholamine]] concentrations without altering [[dopamine]] levels in the [[striatum]] or [[nucleus accumbens]]; in contrast, [[methylphenidate]], a [[dopamine reuptake inhibitor]], was found to increase prefrontal, striatal, and accumbal dopamine levels to the same degree.<ref name = NPP2002>{{cite journal|title=Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder|journal=Neuropsychopharmacology|date=November 2002|volume=27|issue=5|pages=699–711|doi=10.1016/S0893-133X(02)00346-9|pmid=12431845|author1=Bymaster, FP |author2=Katner, JS |author3=Nelson, DL |author4=Hemrick-Luecke, SK |author5=Threlkeld, PG |author6=Heiligenstein, JH |author7=Morin, SM |author8=Gehlert, DR |author9=Perry, KW |url=http://www.nature.com/npp/journal/v27/n5/pdf/1395936a.pdf|format=PDF}}</ref> In mice, atomoxetine was also found to increase prefrontal catecholamine levels without affecting striatal or accumbal levels.<ref name = PMID20403082>{{cite journal|last1=Koda|first1=K|last2=Ago|first2=Y|last3=Cong|first3=Y|last4=Kita|first4=Y|last5=Takuma|first5=K|last6=Matsuda|first6=T|title=Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.|journal=Journal of neurochemistry|date=July 2010|volume=114|issue=1|pages=259–70|doi=10.1111/j.1471-4159.2010.06750.x|pmid=20403082}}</ref>

 
Atomoxetine's status as a [[serotonin transporter]] (SERT) inhibitor at clinical doses in humans is uncertain. A [[Positron emission tomography|PET imaging]] study on [[rhesus monkey]]s found that atomoxetine occupied >90% and >85% of neural NET and SERT, respectively.<ref name="DingNaganawa2014">{{cite journal|last1=Ding|first1=Y.-S.|last2=Naganawa|first2=M.|last3=Gallezot|first3=J.-D.|last4=Nabulsi|first4=N.|last5=Lin|first5=S.-F.|last6=Ropchan|first6=J.|last7=Weinzimmer|first7=D.|last8=McCarthy|first8=T.J.|last9=Carson|first9=R.E.|last10=Huang|first10=Y.|last11=Laruelle|first11=M.|title=Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD|journal=NeuroImage|volume=86|year=2014|pages=164–171|issn=1053-8119|doi=10.1016/j.neuroimage.2013.08.001|pmid=23933039|quote=The noradrenergic action also exerts an important clinical effect in different antidepressant classes such as desipramine and nortriptyline (tricyclics, prevalent noradrenergic effect), reboxetine and atomoxetine (relatively pure noradrenergic reuptake inhibitor (NRIs)), and dual action antidepressants such as the serotonin noradrenaline reuptake inhibitors (SNRIs), the noradrenergic and dopaminergic reuptake inhibitor (NDRI) bupropion, and other compounds (e.g., mianserin, mirtazapine), which enhance the noradrenergic transmission}}</ref> However, both mouse and rat microdialysis studies have failed to find an increase in extracellular [[serotonin]] in the prefrontal cortex following acute or chronic atomoxetine treatment.<ref name = NPP2002/><ref name = PMID20403082/> Supporting atomoxetine's selectivity, a human study found no effects on platelet serotonin uptake (a marker of SERT inhibition) and inhibition of the [[Antihypotensive agent|pressor]] effects of [[tyramine]] (a marker of NET inhibition).<ref>{{cite journal|last1=Zerbe|first1=RL|last2=Rowe|first2=H|last3=Enas|first3=GG|last4=Wong|first4=D|last5=Farid|first5=N|last6=Lemberger|first6=L|title=Clinical pharmacology of tomoxetine, a potential antidepressant.|journal=The Journal of pharmacology and experimental therapeutics|date=January 1985|volume=232|issue=1|pages=139–43|pmid=3965689}}</ref>

 
Atomoxetine also reversibly inhibits [[GIRK]] currents in [[Xenopus|''Xenopus'' oocytes]] in a concentration-dependent, voltage-independent, and time-independent manner.<ref name = PMID20393461>{{cite journal|last1=Kobayashi|first1=T|last2=Washiyama|first2=K|last3=Ikeda|first3=K|title=Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.|journal=Neuropsychopharmacology|date=June 2010|volume=35|issue=7|pages=1560–9|doi=10.1038/npp.2010.27|pmid=20393461}}</ref> K<sub>ir</sub>3.1/3.2 [[ion channel]]s are opened downstream of [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]], [[Alpha-2 adrenergic receptor|α<sub>2</sub>]], [[Dopamine receptor D2|D<sub>2</sub>]], and [[Adenosine A1 receptor|A<sub>1</sub>]] stimulation, as well as other [[Gi alpha subunit|G<sub>i</sub>]]-coupled receptors.<ref name = PMID20393461/> Therapeutic concentrations of atomoxetine are within range of interacting with GIRKs, especially in CYP2D6 poor metabolizers.<ref name = PMID20393461/> It is not known whether this contributes to the therapeutic effects of atomoxetine in ADHD.

 
4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for [[opioid receptor]]s, acting as an antagonist at [[Mu opioid receptor|μ-opioid receptors]] and a partial agonist at [[Kappa opioid receptor|κ-opioid receptors]].<ref name="PMID15225731">{{cite journal|last=Creighton|first=CJ|author2=Ramabadran, K|author3= Ciccone, PE|author4= Liu, J|author5= Orsini, MJ|author6= Reitz, AB|title=Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.|journal=Bioorganic & Medicinal Chemistry Letters|date=2 August 2004|volume=14|issue=15|pages=4083–5|pmid=15225731|doi=10.1016/j.bmcl.2004.05.018}}</ref> It is not known whether this contributes to the therapeutic effects of atomoxetine in ADHD.

 
There has been some suggestion that atomoxetine might be a helpful adjunct in people with [[major depression]], particularly in cases with concomitant ADHD.<ref>{{cite journal |vauthors=Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J |lastauthoramp=yes |title=Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity |journal=The Journal of Clinical Psychiatry |volume=67|issue=3 |pages=415–20 |date=March 2006|pmid=16649828 |doi=10.4088/JCP.v67n0312}}</ref><ref>{{cite journal |vauthors=Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH |title=Augmentation with open-label atomoxetine for partial or non-response to antidepressants |journal=The Journal of Clinical Psychiatry|volume=66 |issue=10 |pages=1234–8 |date=October 2005 |pmid=16259536 |doi=10.4088/JCP.v66n1005}}</ref><ref>{{cite journal |vauthors=Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J |lastauthoramp=yes |title=Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms |journal=Journal of the American Academy of Child and Adolescent Psychiatry |volume=44|issue=9|pages=915–24 |date=September 2005 |pmid=16113620|doi=10.1097/01.chi.0000169012.81536.38}}</ref>

 
* [http://medlibrary.org/drugs/other/strattera.html Detailed Strattera Consumer Information: Uses, Precautions, Side Effects]
